Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) gapped down before the market opened on Thursday . The stock had previously closed at $12.90, but opened at $12.50. Ginkgo Bioworks shares last traded at $12.34, with a volume of 161,861 shares changing hands.
Ginkgo Bioworks Trading Down 3.2 %
The stock has a 50 day moving average of $9.73. The stock has a market capitalization of $733.44 million, a price-to-earnings ratio of -0.98 and a beta of 1.09.
Hedge Funds Weigh In On Ginkgo Bioworks
A number of large investors have recently added to or reduced their stakes in DNA. AQR Capital Management LLC bought a new position in shares of Ginkgo Bioworks during the second quarter valued at about $3,391,000. Renaissance Technologies LLC purchased a new stake in Ginkgo Bioworks during the 2nd quarter valued at about $2,128,000. XTX Topco Ltd bought a new position in Ginkgo Bioworks during the 2nd quarter worth approximately $312,000. Mackenzie Financial Corp purchased a new position in Ginkgo Bioworks in the 2nd quarter worth approximately $251,000. Finally, Erste Asset Management GmbH bought a new stake in Ginkgo Bioworks in the third quarter valued at approximately $4,075,000. Hedge funds and other institutional investors own 78.63% of the company's stock.
Ginkgo Bioworks Company Profile
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Featured Stories
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
